Fritextsökning
Innehållstyper
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Söder...
-
Lund University’s record-breaking recruitment – attracting researchers from around the world
The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.
-
FDA approves Gilead’s HIV injection: “Historic day”
Gilead Sciences’ preventive HIV drug, lenacapavir, was approved on Wednesday by the U.S. Food and Drug Administration (FDA), sparking new hope for finally break...
-
Astra Zeneca faces potential multimillion-dollar fines in China
Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...
-
Orexo utser tysk biotechprofil till styrelseordförande
Uppsalabolaget Orexo har utsett Friedrich von Bohlen und Halbach till ny styrelseordförande.
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Miljardsatsning ska få forskare att lämna USA för EU
Vita husets krav på ökat inflytande över universiteten har väckt oro för hotad akademisk frihet. Nu ska en ny EU-förorning locka amerikanska forskare till Europ...
-
Aqilion's licensing journey: From Merck partnership to new opportunities
Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...
-
Quretech granted a European patent for a new type of antibiotic
The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.
-
Emma Spak ska styra regionernas nya vårdberedskap
Läkaren Emma Spak utses till chef för Nationell samverkan och planering, NSPL.
-
Svensk läkemedelsdoldis ny på lista över dollarmiljardärer
Doldisen Per Sandberg, storägare i läkemedelsbolaget Camurus, hör till en av världens mest förmögna personer. Bland de namn som hängt med från tidigare års list...
-
600 million SEK for life science - "Should not be the country of moderation"
Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
Efter tullhoten – Novartis satsar 230 miljarder i USA
Den schweiziska läkemedelsjätten Novartis planerar att investera 23 miljarder dollar, motsvarande 230 miljarder kronor, under de närmaste fem åren för att utöka...
-
Italian pharmaceutical company buys rights to immunotherapy from Sanofi
Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).
-
Norway rejects national life science strategy – sees no need
The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.
-
After the threat of tariffs – Novartis invests 230 billion in the USA
Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...
-
Xbrane enters licensing agreement with Indian generics giant
Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.
-
Partial court victory for entrepreneur who lost his company
Swedish life science entrepreneur Mikael Kubista has won the first round against a law firm that he, along with other co-owners, sued for negligent advice in co...
-
Ranking: Top 10 highest-paid CEOs in pharma
It's nice to hear that things go well for others, right? Some of those who have done really well – at least financially – are listed here in the ranking of the ...
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
Björn Arvidsson will lead research and innovation in Region Uppsala
The Swedish life science profile Björn Arvidsson has been appointed Director of Research and Innovation for Region Uppsala.
-
Björn Arvidsson ska driva forskning och innovation i Region Uppsala
Life science-profilen Björn Arvidsson har utsetts till forsknings- och innovationsdirektör för Region Uppsala.
-
“Research is always a lot of failures and a few successes”
Gene therapies open up fantastic possibilities, but they are also extremely expensive to produce. Genenova aims to change that and make the treatments accessibl...